Global Myasthenia Gravis (MG) Epidemiology Forecast 2018-2027 - ResearchAndMarkets.com

September 27, 2018

DUBLIN--(BUSINESS WIRE)--Sep 27, 2018--The “Myasthenia Gravis (MG) - Epidemiology Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.

Myasthenia Gravis (MG) - Epidemiology Forecast to 2027′ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Myasthenia Gravis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Myasthenia Gravis (MG) epidemiology division provide the insights about historical and current patient pool and forecasted trend for 7 major countries. The epidemiology data for Myasthenia Gravis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology {total prevalent cases, gender-specific cases, severity-specific prevalent cases [Class I, Class II (Class IIa, IIb), Class III (Class IIIa, IIIb), Class IV & Class V], auto-antibodies specific prevalent cases [Anti-AchR Ab (+ve), Anti-MuSK Ab (+ve), Double seronegative] and diagnosed cases} scenario of Myasthenia Gravis (MG) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

Key Topics Covered:

1. Key Insights

2. Myasthenia Gravis Market Overview at a Glance

3. Market Share (%) Distribution of MG in 2017

4. Market Share (%) Distribution of MG in 2027

5. Disease Overview: Myasthenia Gravis

6. Epidemiology and Patient Population

7. Market Drivers

8. Market Barriers

9. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/xf7qw9/global_myasthenia?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180927005820/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/27/2018 02:43 PM/DISC: 09/27/2018 02:43 PM


Update hourly